Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics Inc (CATX) is a clinical-stage radiopharmaceutical company advancing targeted alpha therapies for cancer treatment. This page provides investors and medical professionals with essential updates on the company’s pioneering work in theranostics, which combines therapeutic isotopes with precision imaging diagnostics.
Access real-time announcements including clinical trial milestones, regulatory developments, and strategic partnerships. Our curated news collection offers transparent insights into the company’s progress with 212Pb-based therapies and their applications across oncology specialties.
Key updates cover FDA submissions, peer-reviewed research findings, and manufacturing advancements. Bookmark this page to monitor how CATX’s proprietary targeting peptides and isotope delivery systems are reshaping radiation oncology.
Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated interim results from their Phase 1/2a trial of [212Pb]VMT-α-NET will be presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025, in San Francisco. The presentation, titled 'Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs),' will be featured in Poster Session B.
The company will host a webcast conference call on January 24, 2025, at 8:00 am ET to discuss the presented data. Dr. Richard L. Wahl, lead investigator and Professor of Radiology at Washington University School of Medicine, will participate alongside the management team. The initial results were previously presented with data cut-off on October 31, 2024.
Perspective Therapeutics (NYSE AMERICAN: CATX) has provided strategic updates and priorities for the next 12-18 months. The company reported preliminary unaudited cash and equivalents of $227.8M as of December 31, 2024, expected to fund operations into late 2026.
The company is advancing three clinical programs: VMT-α-NET for neuroendocrine tumors, which has shown promising safety data and clinical activity in 18 patients; VMT01 for melanoma treatment, demonstrating favorable safety profile and some clinical responses; and PSV359, a new asset targeting FAP-α in solid tumors, with potential enrollment starting mid-2025.
Additionally, four new assets are being evaluated for IND development. The company is expanding its manufacturing capabilities through improving existing facilities and developing recently acquired sites.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on advanced cancer treatments, has announced its participation in two major healthcare conferences in San Francisco.
CEO Thijs Spoor will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, from 3:45 p.m. to 4:25 p.m. PT at The Westin St. Francis Hotel's Elizabethan B room. Additionally, the company will present at the Biotech Showcase conference on Tuesday, January 14, 2025, at 1:30 p.m. PT, taking place at the Hilton San Francisco - Union Square's Yosemite A Ballroom.
The management team will be available for one-on-one meetings with investors and strategic partners at both conferences, with interested parties directed to contact events@perspectivetherapeutics.com for scheduling.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, has appointed Juan Graham as its new Chief Financial Officer (CFO) effective January 6, 2025. Jonathan Hunt, the former CFO, will transition to the role of Chief Accounting Officer (CAO). The company's CEO, Thijs Spoor, emphasized the strategic importance of this change as Perspective advances its radiopharmaceutical technology platform and builds manufacturing infrastructure.
Mr. Graham brings nearly 25 years of global experience in life sciences, having previously served as CFO at FibroGen, where he led global finance, capital formation, and strategic initiatives. Before that, he held various finance and business development roles at Johnson & Johnson. Mr. Graham holds an MBA from McGill University and a bachelor's degree from Tec de Monterrey.
Perspective Therapeutics has delivered initial clinical data for two new potential medicines and plans to advance further clinical programs and new initiatives under Mr. Graham's financial leadership.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on cancer treatments, has announced its participation in two major investor conferences in December 2024. The company's senior leadership will be available for one-on-one meetings with investors at both events.
The first appearance will be at the 36th Annual Piper Healthcare Conference in New York on December 3, featuring a fireside chat from 10:00-10:25 AM ET. The second event is the 7th Annual Evercore HealthCONx in Coral Gables, FL on December 5, with a fireside chat scheduled for 10:50-11:10 AM ET. Both events will be webcasted and available for replay for 90 days through the company's investor website.
Perspective Therapeutics announced initial results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors at the 2024 NANETS Symposium. The trial showed favorable safety profile with no dose-limiting toxicities at tested doses (2.5 and 5.0 mCi). Eight of nine patients achieved durable disease control, with six showing measurable tumor volume reduction. One patient achieved confirmed response per RECIST v1.1. The Safety Monitoring Committee recommended proceeding with dose escalation and expanding patient enrollment at 5.0 mCi. The company plans to consult with FDA for Cohort 3 initiation.
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 expressing neuroendocrine tumors,' will be delivered by Dr. Richard L. Wahl on November 22, 2024. The company will host a conference call on November 21 to discuss the data, featuring Dr. Wahl and including a Q&A session.
Perspective Therapeutics (NYSE AMERICAN: CATX) reported Q3 2024 financial results and business updates. The company has $267.8 million in cash and investments, expected to fund operations into mid-2026. Key developments include advancing [212Pb]VMT01 trials in melanoma patients and [212Pb]VMT-α-NET in neuroendocrine tumors. The company started shipping from a second manufacturing facility in Somerset, New Jersey, and purchased additional facilities in Houston, Chicago, and Los Angeles. Q3 2024 showed a net loss of $15.1 million ($0.21 per share), with research and development expenses at $12.0 million and general administrative expenses at $7.0 million.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, will report its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the market closes. The press release will be available in the newsroom section of the Company's website.
Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on cancer treatments, has announced its participation in four major investor conferences this November. The company will attend the Truist Securities BioPharma Symposium (Nov 7) in New York for one-on-one meetings, the UBS Global Healthcare Conference (Nov 13) in California featuring a fireside chat, the Stifel Healthcare Conference (Nov 18) in New York with a fireside chat, and the Jefferies London Healthcare Conference (Nov 19-21) for one-on-one meetings. Webcasts of applicable events will be available live and archived for 90 days on the company's investor website.
FAQ
What is the current stock price of Perspective Therapeutics (CATX)?
What is the market cap of Perspective Therapeutics (CATX)?
